Patents by Inventor Steen Knudsen

Steen Knudsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10570457
    Abstract: The present invention provides drug response predictors and biomarkers useful for assessing the responsiveness of a subject to treatment with one or more target drugs of interest, such as 5-fluorouracil (5-FU), irinotecan, and/or oxaliplatin. In particular, the invention provides methods useful in determining whether a subject is sensitive or resistant to a target drug by, e.g., measuring the expression level of one or more biomarkers of sensitivity and/or resistance to the drug in a biological sample obtained from the subject. The invention further features devices and kits for assessing target drug responsiveness in a subject, for example, by determining the expression level of such biomarkers.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: February 25, 2020
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Patent number: 10392667
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment, such as fulvestrant.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: August 27, 2019
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Publication number: 20190231795
    Abstract: Featured are methods of treating a patient with cancer by administering, e.g., a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome composition (e.g., LiPlaCis). The patient may be assessed for their responsiveness to the liposomal therapy prior to treatment using the methods, devices, and kits also described herein for detecting a level of one or more biomarkers in a sample from the patient with cancer.
    Type: Application
    Filed: January 25, 2019
    Publication date: August 1, 2019
    Inventors: Steen KNUDSEN, Peter Buhl JENSEN, Ulla Hald BUHL, Annie RASMUSSEN, Mogens Winkel MADSEN
  • Publication number: 20180334724
    Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient with cancer or determining the responsiveness of a patient with cancer to a treatment, such as treatment with an anthracycline. The invention further includes methods of treating a patient with cancer by administering, e.g., the anthracycline.
    Type: Application
    Filed: May 14, 2018
    Publication date: November 22, 2018
    Inventor: Steen KNUDSEN
  • Publication number: 20180202004
    Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient having cancer or determining the responsiveness of a patient having cancer to a treatment, such as treatment with a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome. The invention further includes methods of treating a patient having cancer by administering, e.g., the liposome.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 19, 2018
    Inventor: Steen KNUDSEN
  • Publication number: 20180100197
    Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.
    Type: Application
    Filed: July 12, 2017
    Publication date: April 12, 2018
    Inventor: Steen KNUDSEN
  • Publication number: 20180087113
    Abstract: The present invention features methods, devices, and kits for detecting gene expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as APO010. The invention further includes methods of treating a patient having cancer by administering, e.g., APO010.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 29, 2018
    Inventor: Steen KNUDSEN
  • Publication number: 20170283884
    Abstract: The present invention provides drug response predictors and biomarkers useful for assessing the responsiveness of a subject to treatment with one or more target drugs of interest, such as 5-fluorouracil (5-FU), irinotecan, and/or oxaliplatin. In particular, the invention provides methods useful in determining whether a subject is sensitive or resistant to a target drug by, e.g., measuring the expression level of one or more biomarkers of sensitivity and/or resistance to the drug in a biological sample obtained from the subject. The invention further features devices and kits for assessing target drug responsiveness in a subject, for example, by determining the expression level of such biomarkers.
    Type: Application
    Filed: September 25, 2015
    Publication date: October 5, 2017
    Inventor: Steen KNUDSEN
  • Patent number: 9725769
    Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: August 8, 2017
    Assignee: Oncology Venture ApS
    Inventor: Steen Knudsen
  • Patent number: 9598734
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying biomarkers, the expression of which correlates to treatment sensitivity or resistance within a patient population or subpopulation.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: March 21, 2017
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Publication number: 20160199399
    Abstract: The invention features methods for predicting responsiveness to chemotherapy drug(s) in cancer patients (e.g., patients with lymphoma (e.g, patients with DLBCL)), by, e.g., determining a level of expression of one or more biomarkers in a biological sample obtained from the patient.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventor: Steen Knudsen
  • Publication number: 20160138111
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment, such as fulvestrant.
    Type: Application
    Filed: February 5, 2014
    Publication date: May 19, 2016
    Inventor: Steen KNUDSEN
  • Publication number: 20140106986
    Abstract: The present invention features microRNAs as biomarkers for prognosing cancer relapse in cancer patient. The present invention also features methods, devices, and kits for this purpose.
    Type: Application
    Filed: June 1, 2012
    Publication date: April 17, 2014
    Applicant: Medical Prognosis Institute A/S
    Inventors: Steen Knudsen, Wiktor Mazin
  • Publication number: 20140094381
    Abstract: A set of biomarkers have been identified that allows one to predict subjects who will respond to an exercise regime in term of cardiorespiratory fitness as assessed by maximal oxygen uptake. These predictions may be used, for example, to predict risk of cardiovascular disease, to design a more effective program for cardiac rehabilitation, to predict capacity for athletic performance or physically demanding occupation, and to predict ability to maintain functional capacity with aging using exercise.
    Type: Application
    Filed: September 6, 2013
    Publication date: April 3, 2014
    Applicants: Medical Prognosis Institute A/S, Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: JAMES TIMMONS, STEEN KNUDSEN, TUOMO RANKINEN, CARL JOHAN SUNDBERG, CLAUDE BOUCHARD
  • Patent number: 8445198
    Abstract: The present invention features methods, kits, and devices for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying gene biomarkers whose expression correlates to treatment sensitivity or resistance within a patient population or subpopulation.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: May 21, 2013
    Assignee: Medical Prognosis Institute
    Inventor: Steen Knudsen
  • Publication number: 20130053275
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying biomarkers, the expression of which correlates to treatment sensitivity or resistance within a patient population or subpopulation.
    Type: Application
    Filed: April 29, 2011
    Publication date: February 28, 2013
    Applicant: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Publication number: 20110195412
    Abstract: A set of biomarkers have been identified that allows one to predict subjects who will respond to an exercise regime in term of cardiorespiratory fitness as assessed by maximal oxygen uptake. These predictions may be used, for example, to predict risk of cardiovascular disease, to design a more effective program for cardiac rehabilitation, to predict capacity for athletic performance or physically demanding occupation, and to predict ability to maintain functional capacity with aging using exercise.
    Type: Application
    Filed: September 4, 2009
    Publication date: August 11, 2011
    Inventors: James Timmons, Steen Knudsen, Tuomo Rankinen, Carl Johan Sundberg, Claude Bouchard
  • Publication number: 20090023149
    Abstract: The present invention features methods, kits, and devices for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying gene biomarkers whose expression correlates to treatment sensitivity or resistance within a patient population or subpopulation.
    Type: Application
    Filed: May 9, 2008
    Publication date: January 22, 2009
    Inventor: Steen Knudsen